Asia-Pacific Journal of Clinical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Do FHIT gene alterations play a role in human solid tumors?
Abstract The fragile histidine triad (FHIT) gene encloses an active common chromosomal fragile site, FRA3B. This gene is known to be associated with genomic instability, apoptosis and DNA damage. FHIT disturbances have been related to carcinogenesis in different types of human tumor. Despite this, there are some controversies about the exact role of the FHIT gene in relation to tumor biology. Several pieces of evidence support the hypothesis that FHIT acts as a tumor suppressor gene. A loss or decrease in the Fhit protein expression appears to be related to tumor progression, poor prognostic factors and lower survival rate...
Source: Asia-Pacific Journal of Clinical Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Lisiane Silveira Zavalhia, Aline Weber Medeiros, Andrew Oliveira Silva, Adriana Vial Roehe Tags: REVIEW ARTICLE Source Type: research

A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane ‐based regimens
ConclusionIn Japanese MBC patients in a real‐world setting, eribulin showed a survival benefit and tolerability similar to that in previous reports. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Yasuko Kikuchi, Yoshihiro Uchida, Kazuo Shirakawa, Hajime Kanauchi, Takayoshi Niwa, Kotoe Nishioka, Keiichirou Tada, Masanori Hashimoto, Hidemitsu Yasuda, Ryoko Sugiura, Hidetaka Kawabata, Yasuyuki Seto, Toshihisa Ogawa Tags: ORIGINAL ARTICLE Source Type: research

Outcomes of Australian patients receiving non ‐funded anti‐PD‐1 immune checkpoint inhibitors for non‐melanoma cancers
ConclusionThe response rates and overall survival of patients with NSCLC, renal carcinoma and triple negative breast cancer of good performance status receiving anti‐PD‐1 therapy outside of a clinical trial are consistent with clinical trial data. However, patients with poor ECOG performance status are unlikely to respond. Careful patient selection and counseling about the potential outcomes of self‐funding treatment in this setting is needed. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Crescens Tiu, Annie Wong, Alan Herschtal, Linda Mileshkin Tags: ORIGINAL ARTICLE Source Type: research

Leptomeningeal enhancement on preoperative brain MRI in patients with glioblastoma and its clinical impact
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - February 23, 2018 Category: Cancer & Oncology Source Type: research

---
Asia-Pacific Journal of Clinical Oncology, Ahead of Print. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - February 23, 2018 Category: Cancer & Oncology Source Type: research

Uterine adenosarcoma in Japan: Clinicopathologic features, diagnosis and management
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - February 14, 2018 Category: Cancer & Oncology Source Type: research

---
Asia-Pacific Journal of Clinical Oncology, Ahead of Print. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - February 14, 2018 Category: Cancer & Oncology Source Type: research

Investigation of estimated glomerular filtration rate and its perioperative change in patients with upper urinary tract urothelial carcinoma: A multi ‐institutional retrospective study
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - February 12, 2018 Category: Cancer & Oncology Source Type: research

---
Asia-Pacific Journal of Clinical Oncology, Ahead of Print. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - February 12, 2018 Category: Cancer & Oncology Source Type: research

Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials
Abstract Toxicities of systemic cancer therapies are often less frequently observed in clinical trials than in clinical practice, due to the careful selection of patients with fewer comorbidities. Although guidelines exist for the estimation of chemotherapy dose, clinical factors like age, comorbid illness and extremes of body habitus are not considered in the method of dose calculation, which can result in significant toxicity. We reviewed the referenced clinical trials from which the evidence‐based curative‐intent cancer treatment protocols were developed for EVIQ, which is an Australian government, online resource. ...
Source: Asia-Pacific Journal of Clinical Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Thiru Prasanna, Jane Beith, Steven Kao, Michael Boyer, Catriona M. McNeil Tags: REVIEW ARTICLE Source Type: research

Leptomeningeal enhancement on preoperative brain MRI in patients with glioblastoma and its clinical impact
ConclusionLME on preoperative brain MRI did not affect the clinical results in glioblastoma patients treated with the Stupp's regimen. However, persistence of LME was associated with poor survival and high possibility of LMS. For these patients, the postoperative adjuvant treatment should focus on palliative aim or more aggressive treatment scheme should be followed to overcome the disastrous results. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Hakyoung Kim, Do Hoon Lim, Tae Gyu Kim, Jung ‐Il Lee, Do‐Hyun Nam, Ho Jun Seol, Doo‐Sik Kong, Jung Won Choi, Yeon‐Lim Suh, Sung Tae Kim Tags: ORIGINAL ARTICLE Source Type: research

Uterine adenosarcoma in Japan: Clinicopathologic features, diagnosis and management
ConclusionsThis study showed the clinicopathologic features of Japanese patients with uterine adenosarcoma and suggested potential solutions for improving prognosis including early treatment based on a timely diagnosis, the development of effective adjuvant therapy for patients at high risk of recurrence, and optimal follow‐up focusing on late recurrence and lung metastasis. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Keisei Tate, Reiko Watanabe, Hiroshi Yoshida, Hanako Shimizu, Takashi Uehara, Mitsuya Ishikawa, Shun ‐ichi Ikeda, Nobuyoshi Hiraoka, Tomoyasu Kato Tags: ORIGINAL ARTICLE Source Type: research

Investigation of estimated glomerular filtration rate and its perioperative change in patients with upper urinary tract urothelial carcinoma: A multi ‐institutional retrospective study
ConclusionsPatients with preoperative normal and moderately reduced eGFR and those with severe and moderate change in postoperative eGFR appeared to have a significantly better prognosis. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Dai Koguchi, Kazumasa Matsumoto, Masaomi Ikeda, Yoshinori Taoka, Takahiro Hirayama, Yasukiyo Murakami, Takuji Utsunomiya, Daisuke Matsuda, Norihiko Okuno, Akira Irie, Masatsugu Iwamura Tags: ORIGINAL ARTICLE Source Type: research

Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule
ConclusionSunitinib administered q.a.d. was safe and effective for mRCC patients. We speculate that the persistent optimal drug plasma concentrations contributed to these effects. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Kojiro Ohba, Yasuyoshi Miyata, Takuji Yasuda, Akihiro Asai, Kensuke Mitsunari, Tomohiro Matsuo, Yasushi Mochizuki, Noriko Matsunaga, Hideki Sakai Tags: ORIGINAL ARTICLE Source Type: research

Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - January 31, 2018 Category: Cancer & Oncology Source Type: research